183 related articles for article (PubMed ID: 33602309)
1. Circulating cell-free epstein-barr virus DNA levels and clinical features in Moroccan patients with nasopharyngeal carcinoma.
Gihbid A; Benzeid R; Faouzi A; Nourlil J; Tawfiq N; Benchakroun N; Guensi A; Bendahhou K; Benider A; El Benna N; Chaoui I; Cadi R; Mzibri ME; Khyatti M
Infect Agent Cancer; 2021 Feb; 16(1):15. PubMed ID: 33602309
[TBL] [Abstract][Full Text] [Related]
2. Levels of plasma Epstein-Barr virus DNA prior and subsequent to treatment predicts the prognosis of nasopharyngeal carcinoma.
Zhao FP; Liu X; Chen XM; Lu J; Yu BL; Tian WD; Wang LU; Xu X; Huang HR; Zhang MW; Li G; Li XP
Oncol Lett; 2015 Nov; 10(5):2888-2894. PubMed ID: 26722258
[TBL] [Abstract][Full Text] [Related]
3. The Dynamic Change in Plasma Epstein-Barr Virus DNA Load over a Long-Term Follow-Up Period Predicts Prognosis in Nasopharyngeal Carcinoma.
Gihbid A; Benzeid R; Faouzi A; El Alami I; Tawfiq N; Benchakroun N; Bendahhou K; Benider A; Guensi A; Khaali W; Chaoui I; El Mzibri M; Cadi R; Khyatti M
Viruses; 2022 Dec; 15(1):. PubMed ID: 36680107
[TBL] [Abstract][Full Text] [Related]
4. Prognostic values of the integrated model incorporating the volume of metastatic regional cervical lymph node and pretreatment serum Epstein-Barr virus DNA copy number in predicting distant metastasis in patients with N1 nasopharyngeal carcinoma.
Yao JJ; Zhou GQ; Wang YQ; Wang SY; Zhang WJ; Jin YN; Zhang F; Li L; Liu LZ; Cheng ZB; Ma J; Qi ZY; Sun Y
Chin J Cancer; 2017 Dec; 36(1):98. PubMed ID: 29284539
[TBL] [Abstract][Full Text] [Related]
5. Circulating pre-treatment Epstein-Barr virus DNA as prognostic factor in locally-advanced nasopharyngeal cancer in a non-endemic area.
Alfieri S; Iacovelli NA; Marceglia S; Lasorsa I; Resteghini C; Taverna F; Mazzocchi A; Orlandi E; Guzzo M; Bianchi R; Fanti D; Pala L; Racca S; Dvir R; Quattrone P; Gloghini A; Volpi CC; Granata R; Bergamini C; Locati L; Licitra L; Bossi P
Oncotarget; 2017 Jul; 8(29):47780-47789. PubMed ID: 28562354
[TBL] [Abstract][Full Text] [Related]
6. Proposed modifications and incorporation of plasma Epstein-Barr virus DNA improve the TNM staging system for Epstein-Barr virus-related nasopharyngeal carcinoma.
Guo R; Tang LL; Mao YP; Du XJ; Chen L; Zhang ZC; Liu LZ; Tian L; Luo XT; Xie YB; Ren J; Sun Y; Ma J
Cancer; 2019 Jan; 125(1):79-89. PubMed ID: 30351466
[TBL] [Abstract][Full Text] [Related]
7. Pretherapy quantitative measurement of circulating Epstein-Barr virus DNA is predictive of posttherapy distant failure in patients with early-stage nasopharyngeal carcinoma of undifferentiated type.
Leung SF; Chan AT; Zee B; Ma B; Chan LY; Johnson PJ; Lo YM
Cancer; 2003 Jul; 98(2):288-91. PubMed ID: 12872347
[TBL] [Abstract][Full Text] [Related]
8. Plasma Epstein-Barr virus DNA and residual disease after radiotherapy for undifferentiated nasopharyngeal carcinoma.
Chan AT; Lo YM; Zee B; Chan LY; Ma BB; Leung SF; Mo F; Lai M; Ho S; Huang DP; Johnson PJ
J Natl Cancer Inst; 2002 Nov; 94(21):1614-9. PubMed ID: 12419787
[TBL] [Abstract][Full Text] [Related]
9. Clinical implications of hepatitis B viral infection in Epstein-Barr virus-associated nasopharyngeal carcinoma.
Xu T; Huang Z; Deng Y; Wang S; Su B; Wei W; Wang D; Jiang J; Li A; Zhang G; Yang H; Claret FX; Hu W
J Clin Virol; 2015 Mar; 64():64-71. PubMed ID: 25728081
[TBL] [Abstract][Full Text] [Related]
10. Long-term prognostic effects of plasma epstein-barr virus DNA by minor groove binder-probe real-time quantitative PCR on nasopharyngeal carcinoma patients receiving concurrent chemoradiotherapy.
Lin JC; Wang WY; Liang WM; Chou HY; Jan JS; Jiang RS; Wang JY; Twu CW; Liang KL; Chao J; Shen WC
Int J Radiat Oncol Biol Phys; 2007 Aug; 68(5):1342-8. PubMed ID: 17449194
[TBL] [Abstract][Full Text] [Related]
11. Plasma Epstein-Barr viral DNA load at midpoint of radiotherapy course predicts outcome in advanced-stage nasopharyngeal carcinoma.
Leung SF; Chan KC; Ma BB; Hui EP; Mo F; Chow KC; Leung L; Chu KW; Zee B; Lo YM; Chan AT
Ann Oncol; 2014 Jun; 25(6):1204-8. PubMed ID: 24638904
[TBL] [Abstract][Full Text] [Related]
12. The diagnostic and prognostic values of plasma Epstein-Barr virus DNA for residual cervical lymphadenopathy in nasopharyngeal carcinoma patients: a retrospective study.
Liu SL; Sun XS; Li XY; Tang LQ; Chen QY; Lin HX; Liang YJ; Yan JJ; Lin C; Guo SS; Liu LT; Li Y; Xie HJ; Tang QN; Liang H; Guo L; Mai HQ
Cancer Commun (Lond); 2019 Mar; 39(1):14. PubMed ID: 30925939
[TBL] [Abstract][Full Text] [Related]
13. Circulating Epstein-Barr virus microRNAs BART7-3p and BART13-3p as novel biomarkers in nasopharyngeal carcinoma.
Lu T; Guo Q; Lin K; Chen H; Chen Y; Xu Y; Lin C; Su Y; Chen Y; Chen M; Zheng Y; Ye Y; Lin S; Zong J; Pan J
Cancer Sci; 2020 May; 111(5):1711-1723. PubMed ID: 32155300
[TBL] [Abstract][Full Text] [Related]
14. Evaluation of plasma Epstein-Barr virus DNA load to distinguish nasopharyngeal carcinoma patients from healthy high-risk populations in Southern China.
Ji MF; Huang QH; Yu X; Liu Z; Li X; Zhang LF; Wang P; Xie SH; Rao HL; Fang F; Guo X; Liu Q; Hong MH; Ye W; Zeng YX; Cao SM
Cancer; 2014 May; 120(9):1353-60. PubMed ID: 24477877
[TBL] [Abstract][Full Text] [Related]
15. Noninvasive diagnosis of nasopharyngeal carcinoma: nasopharyngeal brushings reveal high Epstein-Barr virus DNA load and carcinoma-specific viral BARF1 mRNA.
Stevens SJ; Verkuijlen SA; Hariwiyanto B; Harijadi ; Paramita DK; Fachiroh J; Adham M; Tan IB; Haryana SM; Middeldorp JM
Int J Cancer; 2006 Aug; 119(3):608-14. PubMed ID: 16572427
[TBL] [Abstract][Full Text] [Related]
16. Comparison of plasma Epstein-Barr virus (EBV) DNA levels and serum EBV immunoglobulin A/virus capsid antigen antibody titers in patients with nasopharyngeal carcinoma.
Shao JY; Li YH; Gao HY; Wu QL; Cui NJ; Zhang L; Cheng G; Hu LF; Ernberg I; Zeng YX
Cancer; 2004 Mar; 100(6):1162-70. PubMed ID: 15022282
[TBL] [Abstract][Full Text] [Related]
17. Prognostic Value of Plasma Epstein-Barr Virus DNA for Local and Regionally Advanced Nasopharyngeal Carcinoma Treated With Cisplatin-Based Concurrent Chemoradiotherapy in Intensity-Modulated Radiotherapy Era.
Chen WH; Tang LQ; Guo SS; Chen QY; Zhang L; Liu LT; Qian CN; Guo X; Xie D; Zeng MS; Mai HQ
Medicine (Baltimore); 2016 Feb; 95(5):e2642. PubMed ID: 26844482
[TBL] [Abstract][Full Text] [Related]
18. Tumor heterogeneity measured on F-18 fluorodeoxyglucose positron emission tomography/computed tomography combined with plasma Epstein-Barr Virus load predicts prognosis in patients with primary nasopharyngeal carcinoma.
Chan SC; Chang KP; Fang YD; Tsang NM; Ng SH; Hsu CL; Liao CT; Yen TC
Laryngoscope; 2017 Jan; 127(1):E22-E28. PubMed ID: 27435352
[TBL] [Abstract][Full Text] [Related]
19. Combining pretreatment plasma Epstein-Barr virus DNA level and cervical node necrosis improves prognostic stratification in patients with nasopharyngeal carcinoma: A cohort study.
Du YY; Luo DH; Sun XS; Tang LQ; Mai HQ; Chen QY; Zhong JH; Mai DM; Zhang WR; Chen WH; Mo HY
Cancer Med; 2019 Nov; 8(16):6841-6852. PubMed ID: 31513364
[TBL] [Abstract][Full Text] [Related]
20. Clinical significance of plasma Epstein-Barr Virus DNA loads in a large cohort of Malaysian patients with nasopharyngeal carcinoma.
Chai SJ; Pua KC; Saleh A; Yap YY; Lim PV; Subramaniam SK; Lum CL; Krishnan G; Mahiyuddin WR; ; Teo SH; Khoo AS; Yap LF
J Clin Virol; 2012 Sep; 55(1):34-9. PubMed ID: 22739102
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
